Περίληψη:
Monoclonal gammopathy of undetermined significance (MGUS) was identified
in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of
age or older. The risk of progression to multiple myeloma, Waldenstrom’s
macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is
approximately 1% per year. Low-risk MGUS is characterized by having an
M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio.
Patients should be followed with serum protein electrophoresis at six
months and, if stable, can be followed every 2-3 years or when symptoms
suggestive of a plasma cell malignancy arise. Patients with intermediate
and high-risk MGUS should be followed in 6 months and then annually for
life. The risk of smoldering (asymptomatic) multiple myeloma (SMM)
progressing to multiple myeloma or a related disorder is 10% per year
for the first 5 years, 3% per year for the next 5 years and 1-2% per
year for the next 10 years. Testing should be done 2-3 months after the
initial recognition of SMM. If the results are stable, the patient
should be followed every 4-6 months for 1 year and, if stable, every
6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60;
published online 22 April 2010
Συγγραφείς:
Kyle, R. A.
Durie, B. G. M.
Rajkumar, S. V.
Landgren, O. and
Blade, J.
Merlini, G.
Kroeger, N.
Einsele, H.
Vesole, D.
H.
Dimopoulos, M.
San Miguel, J.
Avet-Loiseau, H.
Hajek,
R.
Chen, W. M.
Anderson, K. C.
Ludwig, H.
Sonneveld, P.
and Pavlovsky, S.
Palumbo, A.
Richardson, P. G.
Barlogie, B.
and Greipp, P.
Vescio, R.
Turesson, I.
Westin, J. and
Boccadoro, M.
Int Myeloma Working Grp
